Feb 25 - Zydus Lifesciences will launch generic versions of semaglutide injections for ‌obesity and diabetes in India after ‌patent expiry of the Ozempic active ingredient in late March, it said on ...

Throughout the year, Teva had momentum in innovative medicines, scaling its global generics and biosimilars portfolio. On the brand side, Teva said it continued to showcase strong performance of its ...

John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. Emory is the data editor at ...

New Jersey has joined 42 other states in suing global pharmaceutical company Novartis and its spin-off Sandoz for engaging in what they describe as “one of the most egregious examples of ...

I open my emails to find yet another message from a patient about their amphetamine-dextroamphetamine (the generic form of Aderall) no longer working. Dr. Plutchik, my meds no longer seem to be ...

HYDERABAD, Jan 21 (Reuters) - Indian drugmaker Dr Reddy's (REDY.NS), opens new tab, which reported a smaller-than-expected fall in quarterly profit on Wednesday, said that it has received an approval ...

The U.S. Supreme Court has decided to hear a case between Amarin Pharma and generic drug maker Hikma that puts so-called “skinny labels” back in the spotlight. The high court has agreed to make the ...

Prefilled drug delivery device specialist Apiject has signed a lease for a new site in Apex, North Carolina, that will house two blow-fill-seal production lines. The 30,000-square-foot facility will ...

Richard L. Jackson is the founder and CEO of Jackson Healthcare, the parent company of USAntibiotics. The United States leads the world in pharmaceutical innovation. But it is less successful in ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. These highlights were written by the reporters and editors ...

President Donald Trump has been successful in convincing many of the world’s top drugmakers to commit to manufacturing more of their prescription treatments in the U.S. But what about the onshoring of ...